Neonatal Intensive Care Unit, G. d'Annunzio University, Chieti, Italy.
Department of Maternal, Fetal and Neonatal Medicine, ASO SS Antonio, Biagio and C. Arrigo, Alessandria, Italy.
Clin Chem Lab Med. 2022 Jan 11;60(3):317-331. doi: 10.1515/cclm-2021-1012. Print 2022 Feb 23.
Recent advances in perioperative management of adult and pediatric patients requiring open heart surgery (OHS) and cardiopulmonary bypass (CPB) for cardiac and/or congenital heart diseases repair allowed a significant reduction in the mortality rate. Conversely morbidity rate pattern has a flat trend. Perioperative period is crucial since OHS and CPB are widely accepted as a deliberate hypoxic-ischemic reperfusion damage representing the cost to pay at a time when standard of care monitoring procedures can be silent or unavailable. In this respect, the measurement of neuro-biomarkers (NB), able to detect at early stage perioperative brain damage could be especially useful. In the last decade, among a series of NB, S100B protein has been investigated. After the first promising results, supporting the usefulness of the protein as predictor of short/long term adverse neurological outcome, the protein has been progressively abandoned due to a series of limitations. In the present review we offer an up-dated overview of the main S100B and in the peri-operative monitoring of adult and pediatric patients.
近年来，需要进行心脏直视手术（OHS）和体外循环（CPB）的成人和儿科患者的围手术期管理取得了进展，用于治疗心脏和/或先天性心脏病。这使得死亡率显著降低。相反，发病率模式呈平稳趋势。围手术期至关重要，因为 OHS 和 CPB 被广泛认为是一种蓄意的缺氧-缺血再灌注损伤，这是在标准护理监测程序可能无声或不可用时必须付出的代价。在这方面，神经生物标志物（NB）的测量，能够在围手术期早期检测到脑损伤，可能特别有用。在过去的十年中，已经研究了一系列 NB 中的 S100B 蛋白。在最初的一些有前景的结果支持该蛋白作为短期/长期不良神经结局预测因子的有用性之后，由于一系列局限性，该蛋白逐渐被放弃。在本综述中，我们提供了 S100B 和 在成人和儿科患者围手术期监测中的主要用途的最新概述。
